ABOUT ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS

In Section C, contributors will get ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Participants will obtain treatment right up until illness progression or maybe the individuals are unable to tolerate the study drugs.Ubiquitin-connected proteins that control the stability of essential Tremendous enhancer-me